Astrivax

AstriVax operates as a privately owned company that originated as a spin-off from the KU Leuven in the year 2022, leveraging vaccine technology developed at the Rega Institute. With a focus on creating a pioneering Plug & Play vaccine platform, AstriVax utilizes a patented DNA-based approach to initiate self-amplifying live attenuated viruses. This adaptable technology enables AstriVax to produce a diverse array of vaccines for the prevention and treatment of infectious diseases. The company's primary objective is to tackle significant vaccinology challenges by innovating new vaccines that are easily manufacturable, require minimal refrigeration, and deliver comprehensive and enduring protection against a range of viruses.